MovDisordV3, PascalFrancis, Curation, bibRecord, 001859

Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study

Identifieur interne : 001859 ( PascalFrancis/Curation ); précédent : 001858; suivant : 001860

Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study

Auteurs : Claudio Lucetti [Italie] ; Paulo Del Dotto [Italie] ; Gianna Gambaccini [Italie] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Caterina Berti [Italie] ; Giuseppe Rossi [Italie] ; Maria Cristina Bianchi [Italie] ; Michela Tosetti [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie]

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:08-0071401

Descripteurs français

Pascal (Inist)
- Pathologie du système nerveux, Maladie de Parkinson, Traitement, Cortex moteur, Imagerie RMN, Stimulant dopaminergique, Pergolide.

English descriptors

KwdEn :
- Dopamine agonist, Motor cortex, Nervous system diseases, Nuclear magnetic resonance imaging, Parkinson disease, Pergolide, Treatment.

Abstract

The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 22`
A06				`@2 15`
A08	`01`	`1`	`ENG`	`@1 Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study`
A11	`01`	`1`		`@1 LUCETTI (Claudio)`
A11	`02`	`1`		`@1 DEL DOTTO (Paulo)`
A11	`03`	`1`		`@1 GAMBACCINI (Gianna)`
A11	`04`	`1`		`@1 CERAVOLO (Roberto)`
A11	`05`	`1`		`@1 LOGI (Chiara)`
A11	`06`	`1`		`@1 BERTI (Caterina)`
A11	`07`	`1`		`@1 ROSSI (Giuseppe)`
A11	`08`	`1`		`@1 BIANCHI (Maria Cristina)`
A11	`09`	`1`		`@1 TOSETTI (Michela)`
A11	`10`	`1`		`@1 MURRI (Luigi)`
A11	`11`	`1`		`@1 BONUCCELLI (Ubaldo)`
A14	`01`			`@1 Department of Neuroscience, University of Pisa @3 ITA @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 10 aut. @Z 11 aut.`
A14	`02`			`@1 Neurology Unit, Hospital of Viareggio @3 ITA @Z 2 aut.`
A14	`03`			`@1 Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa @3 ITA @Z 7 aut.`
A14	`04`			`@1 Department of Neuroradiology, Hospital of Pisa @3 ITA @Z 8 aut.`
A14	`05`			`@1 Laboratory of Magnetic Resonance, IRCCS Stella Maris @2 Pisa @3 ITA @Z 8 aut. @Z 9 aut.`
A20				`@1 2170-2175`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000162671070050`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 34 ref.`
A47	`01`	`1`		`@0 08-0071401`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 09`
C03	`04`	`X`	`FRE`	`@0 Cortex moteur @5 10`
C03	`04`	`X`	`ENG`	`@0 Motor cortex @5 10`
C03	`04`	`X`	`SPA`	`@0 Corteza motora @5 10`
C03	`05`	`X`	`FRE`	`@0 Imagerie RMN @5 11`
C03	`05`	`X`	`ENG`	`@0 Nuclear magnetic resonance imaging @5 11`
C03	`05`	`X`	`SPA`	`@0 Imaginería RMN @5 11`
C03	`06`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 12`
C03	`06`	`X`	`ENG`	`@0 Dopamine agonist @5 12`
C03	`06`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 12`
C03	`07`	`X`	`FRE`	`@0 Pergolide @2 NK @2 FR @5 13`
C03	`07`	`X`	`ENG`	`@0 Pergolide @2 NK @2 FR @5 13`
C03	`07`	`X`	`SPA`	`@0 Pergolida @2 NK @2 FR @5 13`
C07	`01`	`X`	`FRE`	`@0 Encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Encephalon @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso central @5 38`
C07	`03`	`X`	`FRE`	`@0 Voie motrice @5 39`
C07	`03`	`X`	`ENG`	`@0 Motor pathway @5 39`
C07	`03`	`X`	`SPA`	`@0 Vía motora @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 40`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 40`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 41`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`07`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
N21				`@1 035`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001460

Links to Exploration step

Pascal:08-0071401

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study</title>
<author><name sortKey="Lucetti, Claudio" sort="Lucetti, Claudio" uniqKey="Lucetti C" first="Claudio" last="Lucetti">Claudio Lucetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Del Dotto, Paulo" sort="Del Dotto, Paulo" uniqKey="Del Dotto P" first="Paulo" last="Del Dotto">Paulo Del Dotto</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurology Unit, Hospital of Viareggio</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Berti, Caterina" sort="Berti, Caterina" uniqKey="Berti C" first="Caterina" last="Berti">Caterina Berti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Rossi, Giuseppe" sort="Rossi, Giuseppe" uniqKey="Rossi G" first="Giuseppe" last="Rossi">Giuseppe Rossi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa</s1>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Bianchi, Maria Cristina" sort="Bianchi, Maria Cristina" uniqKey="Bianchi M" first="Maria Cristina" last="Bianchi">Maria Cristina Bianchi</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neuroradiology, Hospital of Pisa</s1>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Tosetti, Michela" sort="Tosetti, Michela" uniqKey="Tosetti M" first="Michela" last="Tosetti">Michela Tosetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Murri, Luigi" sort="Murri, Luigi" uniqKey="Murri L" first="Luigi" last="Murri">Luigi Murri</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0071401</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0071401 INIST</idno>
<idno type="RBID">Pascal:08-0071401</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001460</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001859</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study</title>
<author><name sortKey="Lucetti, Claudio" sort="Lucetti, Claudio" uniqKey="Lucetti C" first="Claudio" last="Lucetti">Claudio Lucetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Del Dotto, Paulo" sort="Del Dotto, Paulo" uniqKey="Del Dotto P" first="Paulo" last="Del Dotto">Paulo Del Dotto</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurology Unit, Hospital of Viareggio</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Berti, Caterina" sort="Berti, Caterina" uniqKey="Berti C" first="Caterina" last="Berti">Caterina Berti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Rossi, Giuseppe" sort="Rossi, Giuseppe" uniqKey="Rossi G" first="Giuseppe" last="Rossi">Giuseppe Rossi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa</s1>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Bianchi, Maria Cristina" sort="Bianchi, Maria Cristina" uniqKey="Bianchi M" first="Maria Cristina" last="Bianchi">Maria Cristina Bianchi</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neuroradiology, Hospital of Pisa</s1>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Tosetti, Michela" sort="Tosetti, Michela" uniqKey="Tosetti M" first="Michela" last="Tosetti">Michela Tosetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Murri, Luigi" sort="Murri, Luigi" uniqKey="Murri L" first="Luigi" last="Murri">Luigi Murri</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Motor cortex</term>
<term>Nervous system diseases</term>
<term>Nuclear magnetic resonance imaging</term>
<term>Parkinson disease</term>
<term>Pergolide</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie du   système nerveux</term>
<term>Maladie de Parkinson</term>
<term>Traitement</term>
<term>Cortex moteur</term>
<term>Imagerie RMN</term>
<term>Stimulant dopaminergique</term>
<term>Pergolide</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>15</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LUCETTI (Claudio)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DEL DOTTO (Paulo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GAMBACCINI (Gianna)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CERAVOLO (Roberto)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LOGI (Chiara)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BERTI (Caterina)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ROSSI (Giuseppe)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BIANCHI (Maria Cristina)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>TOSETTI (Michela)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MURRI (Luigi)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>BONUCCELLI (Ubaldo)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neuroscience, University of Pisa</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology Unit, Hospital of Viareggio</s1>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Epidemiology and Biostatistics Unit, Institute of Clinical Physiology -CNR Pisa</s1>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neuroradiology, Hospital of Pisa</s1>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Laboratory of Magnetic Resonance, IRCCS Stella Maris</s1>
<s2>Pisa</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>2170-2175</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000162671070050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>34 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0071401</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cortex moteur</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Motor cortex</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Corteza motora</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Imagerie RMN</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Imaginería RMN</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Pergolide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Pergolida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Encephalon</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Voie motrice</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Motor pathway</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vía motora</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>035</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001859 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001859 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:08-0071401
   |texte=   Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study

Influences of Dopaminergic Treatment on Motor Cortex in Parkinson Disease : A MRI/MRS Study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri